LGI1 mutations in autosomal dominant and sporadic lateral temporal epilepsy

Istituto di Neuroscienze del CNR, Sezione di Padova, Dipartimento di Scienze Biomediche Sperimentali, Università di Padova, Padova, Italy.
Human Mutation (Impact Factor: 5.05). 04/2009; 30(4):530-6. DOI: 10.1002/humu.20925
Source: PubMed

ABSTRACT Autosomal dominant lateral temporal epilepsy (ADLTE) or autosomal dominant partial epilepsy with auditory features (ADPEAF) is an inherited epileptic syndrome with onset in childhood/adolescence and benign evolution. The hallmark of the syndrome consists of typical auditory auras or ictal aphasia in most affected family members. ADTLE/ADPEAF is associated in about half of the families with mutations of the leucine-rich, glioma-inactivated 1 (LGI1) gene. In addition, de novo LGI1 mutations are found in about 2% of sporadic cases with idiopathic partial epilepsy with auditory features, who are clinically similar to the majority of patients with ADLTE/ADPEAF but have no family history. Twenty-five LGI1 mutations have been described in familial and sporadic lateral temporal epilepsy patients. The mutations are distributed throughout the gene and are mostly missense mutations occurring in both the N-terminal leucine rich repeat (LRR) and C-terminal EPTP (beta propeller) protein domains. We show a tridimensional model of the LRR protein region that allows missense mutations of this region to be divided into two distinct groups: structural and functional mutations. Frameshift, nonsense and splice site point mutations have also been reported that result in protein truncation or internal deletion. The various types of mutations are associated with a rather homogeneous phenotype, and no obvious genotype-phenotype correlation can be identified. Both truncating and missense mutations appear to prevent secretion of mutant proteins, suggesting a loss of function effect of mutations. The function of LGI1 is unclear. Several molecular mechanisms possibly leading to lateral temporal epilepsy are illustrated and briefly discussed.


Available from: Simonetta Andreazza, Mar 20, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mutations in leucine-rich glioma inactivated 1 (LGI1) are linked to human autosomal dominant lateral temporal lobe epilepsy. It has been shown that LGI1 prevents the inactivation of voltage-gated potassium channels, mediates postnatal maturation of glutamatergic synapses, and regulates excitatory neurotransmission. However, other functions of LGI1 in the central nervous system have not been elucidated. We found that LGI1 is involved in the development of the cerebellum and cortex. The thickness of external granule layer was reduced, and foliation was affected in the cerebellum of LGI1 knockout mice. Double staining with Pax6 and BrdU showed a significant inhibition of proliferation of granule cell precursors of knockout embryos. The differentiation of radial glia cells was also suppressed in knockout mice, as shown by increased radial glial cells and decreased Bergmann glias in the areas of the cerebellum and cortex. Thus, our data demonstrate that LGI1 may be an essential player in the development of the brain.
    The Cerebellum 12/2014; 14(1). DOI:10.1007/s12311-014-0628-6 · 2.86 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The field of neuronal surface-directed antibody-mediated diseases of the central nervous system has dramatically expanded in the last few years and now forms an important cluster of treatable neurological conditions. In this review, we focus on three areas. First, we review the demographics, clinical features and treatment responses of these conditions. Second, we consider their pathophysiology and compare autoantibody mechanisms and their effects to genetic or pharmacological disruptions of the target antigens. Third, we discuss areas of controversy within the field, propose possible resolutions, and explore new directions for neuronal surface antibody-mediated diseases.
    Journal of Neurology 12/2014; DOI:10.1007/s00415-014-7600-8 · 3.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Antibody-mediated encephalitis/encephalopathy is increasingly recognized by neurologists as well as pediatricians and psychiatrists, because these antibodies have been detected in cases of intractable epilepsy or atypical psychosis and in some demyelinating diseases, together with typical limbic encephalitis. In these disorders, the autoantibodies to synaptic cell surface antigens, such as anti-N-methyl-d-aspartate receptor, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor, γ-aminobutyric acid B receptor and leucine-rich glioma-inactivated protein 1, have attracted considerable attention. New target antigens are being discovered, and some patients have been shown to produce multiple antibodies, based on the development of easy-to-use detection devices. Each group has characteristic clinical features; however, the disease spectrum has been expanding, after many atypical cases became the subject of antibody tests. To understand the significance of these antibodies in the pathogenesis of autoimmune neurological diseases, the role of each antibody in the disease process should be evaluated. Here, some representative groups are described, together with the roles of the antibodies in the pathogenesis of autoimmune encephalitis/encephalopathy.
    09/2014; 6(1). DOI:10.1111/cen3.12154